Pharmaceutical giant GSK and the University of Oxford are collaborating on developing a cancer vaccine that aims to detect ...

Global biopharma company GSK has invested up to £50 million in a collaboration with Oxford University. The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, aimed at exploring ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK has teamed up with the University of Oxford on a programme that will try to identify the molecular changes in cells in precancerous stages that could form the basis of vaccines to prevent full ...

Cancer has long been one of the most feared diseases in the world. Now, a groundbreaking development in vaccine technology ...

At close: January 23 at 4:00:02 PM EST ...